Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA

Sam Gandy, David S. Knopman, Mary Sano

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
Article number74
JournalMolecular neurodegeneration
Issue number1
StatePublished - Dec 2021


  • Aduhelm® (aducanumab)
  • Amyloid beta
  • Donanemab
  • Gantenerumab
  • Lecanemab

ASJC Scopus subject areas

  • Molecular Biology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this